ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$9.79 USD
-0.14 (-1.41%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.98 +0.19 (1.94%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
ARS Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SPRY 9.79 -0.14(-1.41%)
Will SPRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for SPRY
Is SPRY gaining bearish strength? 1,2,3 Retracement Bearish shows up after slipping 1.41%
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) Gains on Japanese Approval for Neffy Nasal Spray
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
SPRY Gains Approval in Japan for Needle-Free Allergy Treatment